photo of

Details

Role Group Leader / Senior Research Fellow
Research area Genomic Medicine

Contact

Available for student supervision
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening...
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).

Top Publications

  • Cornish, KM, Kraan, CM, Bui, QM, Bellgrove, MA, Metcalfe, SA, Trollor, JN, Hocking, DR, Slater, HR, Inaba, Y, Li, X, et al. Novel methylation markers of the dysexecutive-psychiatric phenotype in FMR1 premutation women.. Neurology 84(16) : 1631 -1638 2015
    view publication
  • Shelton, AL, Cornish, KM, Godler, DE, Clough, M, Kraan, C, Bui, M, Fielding, J. Delineation of the working memory profile in female FMR1 premutation carriers: the effect of cognitive load on ocular motor responses.. Behav Brain Res 282: 194 -200 2015
    view publication
  • Hocking, DR, Kraan, CM, Godler, DE, Bui, QM, Li, X, Bradshaw, JL, Georgiou-Karistianis, N, Metcalfe, SA, Archibald, AD, Turbitt, E, et al. Evidence linking FMR1 mRNA and attentional demands of stepping and postural control in women with the premutation.. Neurobiol Aging 36(3) : 1400 -1408 2015
    view publication
  • Birch, RC, Hocking, DR, Cornish, KM, Menant, JC, Georgiou-Karistianis, N, Godler, DE, Wen, W, Hackett, A, Rogers, C, Trollor, JN. Preliminary evidence of an effect of cerebellar volume on postural sway in FMR1 premutation males.. Genes Brain Behav 14(3) : 251 -259 2015
    view publication
  • Inaba, Y, Schwartz, CE, Bui, QM, Li, X, Skinner, C, Field, M, Wotton, T, Hagerman, RJ, Francis, D, Amor, DJ, et al. Early detection of fragile X syndrome: applications of a novel approach for improved quantitative methylation analysis in venous blood and newborn blood spots.. Clin Chem 60(7) : 963 -973 2014
    view publication

Page 12 of 15